Lv6
2710 积分 2022-02-25 加入
Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial
2天前
已完结
Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial
7天前
已关闭
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
8天前
已完结
Best Practices for the Multidisciplinary Care of Patients With Early‐Stage Driver‐Mutated Non‐Small Cell Lung Cancer
10天前
已完结
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
16天前
已完结
Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-analysis with Bayesian Modeling of Treatment Histories
26天前
已完结
Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization
1个月前
已完结
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial
1个月前
已完结
HIF-2α Inhibitor Combinations Knock Back Kidney Cancer in Two Trials
1个月前
已关闭
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
1个月前
已完结
皖公网安备34019202002308